The Chemiluminescence Immunoassay Market was valued at USD 12.14 billion in 2024 and is projected to reach USD 12.68 billion in 2025 and USD 18.97 billion by 2034, growing at a CAGR of 4.6% during the forecast period 2025–2034, according to Polaris Market Research. Chemiluminescence immunoassay (CLIA) technology applies chemiluminescence detection to immunoassays to measure analytes with high sensitivity and specificity. Demand is driven by the rising prevalence of chronic diseases, the need for advanced diagnostic solutions, advances in assay automation, and a shift toward early disease detection. North America was the largest regional market in 2024.
Technology Segmentation: Sensitivity Versus Throughput
By technology, the Chemiluminescence Immunoassay Market spans chemiluminescence enzyme technology, electrochemiluminescence immunoassay, and microparticle chemiluminescence immunoassay. The electrochemiluminescence immunoassay segment holds a dominant position, recognized for superior sensitivity, precision, and the ability to detect low analyte concentrations, with extensive use in oncology, endocrinology, and infectious disease testing.
The microparticle chemiluminescence immunoassay segment is anticipated to register the highest growth rate. Microparticles increase the surface area for antigen-antibody interactions, improving sensitivity and reducing assay time, which suits laboratories handling large sample volumes and point-of-care settings.
Browse Insights:
https://www.polarismarketresearch.com/industry-analysis/chemiluminescence-immunoassay-market
Product Mix: Reagents Lead, Consumables Accelerate
By product, reagents accounted for the largest share of the Chemiluminescence Immunoassay Market in 2024, while consumables are expected to register the highest growth rate. Rising adoption of disposable consumables, such as cartridges and microplates, aligns with the growing emphasis on infection control and operational efficiency in laboratories and point-of-care settings.
Design innovations that enhance assay sensitivity and throughput, together with the focus on personalized medicine and high-throughput screening, are lifting demand for advanced disposable consumables tailored to specific diagnostic applications.
Sample Type Trends: Blood Dominates, Saliva Gains Momentum
The blood sample segment dominates revenue share because of its reliability, comprehensive diagnostic insight, and routine use in healthcare facilities. The saliva segment, however, is projected to exhibit the highest growth rate, driven by its noninvasive nature and increasing acceptance in diagnostics.
Saliva-based CLIA tests are gaining traction for hormone level assessments, drug testing, and infectious disease applications. Demand for patient-friendly solutions, advances in saliva sample collection, and research into COVID-19 and other respiratory illnesses further support adoption of saliva-based CLIA tests.
Application Insights: Oncology Leads Growth
Infectious diseases hold the largest application share, while oncology is expected to register the highest growth rate, fueled by rising cancer prevalence and the focus on early detection and personalized medicine. CLIA assays are extensively used for tumor marker identification, aiding early diagnosis, prognosis, and treatment monitoring.
Continuous technology advances, demand for noninvasive diagnostic methods, greater awareness of cancer screening programs, and increased healthcare investment all reinforce tumor marker identification as a growth avenue.
Regional Insights and Key Players
North America holds the largest share, while Europe remains significant, led by Germany, France, and the UK, where strong governmental support for research and healthcare innovation meets rising chronic disease prevalence among the aging population. Asia Pacific is expected to witness the highest growth, owing to expanding healthcare infrastructure and increasing healthcare expenditure in China and India, supported by localization of manufacturing by key players and government initiatives to improve diagnostic access in rural areas.
Key players Chemiluminescence Immunoassay include Abbott Laboratories, Siemens Healthineers, Roche Diagnostics, Beckman Coulter (a Danaher Corporation subsidiary), Ortho Clinical Diagnostics (now part of QuidelOrtho), DiaSorin, BioMérieux, Mindray Medical International, Sysmex Corporation, Tosoh Corporation, Shenzhen New Industries Biomedical Engineering (Snibe), Randox Laboratories, Biokit (a subsidiary of Werfen), PerkinElmer, and Fujirebio Diagnostics.
Sysmex and Mindray are leveraging their expertise to capture a significant share of the Asia Pacific market, while smaller players pursue cost-effective solutions and localized manufacturing to enter price-sensitive markets. Larger companies increasingly pursue strategic collaborations, acquisitions, and technological advancements to maintain a competitive edge. In January 2025, bioMérieux acquired SpinChip Diagnostics ASA for EUR 138 million. Strict production norms are listed among the market's restraints and challenges.
More Trending Latest Reports By Polaris Market Research:
earth-observation-small-satellite-market
building-information-modeling-market